Omnicell, Inc.OMCLNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank21
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P21
Within normal range
vs 5Y Ago
-0.9x
Contraction
Streak
2 yr
Consecutive growthRecovering
PeriodValue
2025-1.92%
2024-3.08%
2023-11.13%
202238.64%
20217.92%
20202.21%
20195.86%
2018-1.79%
201714.23%
201664.39%